Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML : A Multicenter Study of the ECLA Group
American Journal of Hematology · 2026-08 · 101 (8) · 1938-1953
DOI: 10.1002/ajh.70377 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 26.05.2026. Verfasst von Jiajia Pan und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Histone-Lysine N-Methyltransferase, Myeloid-Lymphoid Leukemia Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Key Research and Development Program of Zhejiang Province.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) harboring KMT2A rearrangement ( KMT2A r) was generally associated with poor prognosis. We enrolled 490 patients with KMT2A r from the East China Leukemia Alliance between March 2013 and August 2025. KMT2A::MLLT3 was the most frequent KMT2Ar (31.6%), followed by KMT2A::MLLT4 (25.1%), KMT2A::ELL (20%), and KMT2A::MLLT10 (12.7%). KMT2A::MLLT4 showed an inferior prognosis. The most co‐occurring gene mutations were KRAS (20.1%), NRAS (19.0%), TET2 (10.2%), WT1 (8.6%), and PTPN11 (7.4%). Trisomy 8 was more common in patients < 60 years, while FLT3‐ITD was only detected in patients < 60 years. With a median follow‐up time of 42.6 months, the median overall survival (OS) of all patients was 30.9 months, and the 3‐year OS rate was 49.9%. Patients treated with venetoclax plus intensive chemotherapy (Ven+IC) showed the best composite complete remission (CRc) rate and OS compared to intensive chemotherapy, venetoclax plus reduced‐intensive chemotherapy, and reduced‐intensive chemotherapy (CRc rate: 89.5% vs. 62.4% vs. 57.3% vs. 61.4%; median OS: not reached vs. 39.9 months vs. 34.8 months vs. 12.7 months). Multivariate analysis identified multiparameter flow cytometry minimal residual disease negativity post‐induction therapy, allogeneic hematopoietic stem cell transplantation, and Ven+IC as independent favorable prognostic factors for event‐free survival (EFS), and KMT2A::MLLT4 fusion, EVI1 overexpression were independent unfavorable prognostic factors for EFS. In summary, our study showed characteristics and prognostic implications in newly diagnosed KMT2A r AML in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China.
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, China.
- Zhejiang University Cancer Center, Hangzhou, China.
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Hematology, Xuzhou Central Hospital, Southeast University, Xuzhou, China.
ORCID-Profile: Ying Lu, Chunyan Ji, Zhiling Yan, Huawei Jiang, Nianci Chen, Hongyan Tong, Jie Jin
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Key Research and Development Program of Zhejiang Province
- Zhejiang Provincial Nature Science Foundation of China
Zitieren
APA
Pan, J., Fu, C., Ling, Q., Lu, Y., Shi, Y., Zhang, Y., Wang, S., Ji, C., Qian, S., Huang, Z., Ge, Z., Zhang, J., Ouyang, G., Jin, C., Lu, Q., Huang, L., Kong, H., Zhu, Y., Yan, Z., …, & East China Leukemia Alliance (2026). Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML : A Multicenter Study of the ECLA Group. American Journal of Hematology, 101(8), 1938-1953. https://doi.org/10.1002/ajh.70377
Vancouver
Pan J, Fu C, Ling Q, Lu Y, Shi Y, Zhang Y, et al. Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML : A Multicenter Study of the ECLA Group. American Journal of Hematology. 2026;101(8):1938-1953. doi:10.1002/ajh.70377
BibTeX
@article{Pan2026,
author = {Pan, Jiajia and Fu, Chunmei and Ling, Qing and Lu, Ying and Shi, Yifen and Zhang, Yunxiang and Wang, Shaoyuan and Ji, Chunyan and Qian, Shenxian and Huang, Zhenqi and Ge, Zheng and Zhang, Jingcheng and Ouyang, Guifang and Jin, Chenghao and Lu, Quanyi and Huang, Li and Kong, Hongwei and Zhu, Yu and Yan, Zhiling and Liu, Debin and Jiang, Huawei and Chen, Nianci and Lin, Xiangjie and Zhou, Yile and Zhang, Yi and Li, Xia and Tong, Hongyan and Jin, Jie and Chen, Suning and Wang, Huafeng and East China Leukemia Alliance, East China Leukemia Alliance},
title = {Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML : A Multicenter Study of the ECLA Group},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {8},
pages = {1938--1953},
doi = {10.1002/ajh.70377}
}
EUVIMED